in



Immunoenzymatic kits for the diagnostics of Yersinia infections

ELISA, **IMMUNOBLOT**, and **MICROBLOT-ARRAY** kits are optimized and validated for detection of specific IgA, IgG, and IgM antibodies in human serum or plasma



Diagnostic kits are intended for professional use in the laboratory.





Yersinia are pathogenic gram-negative bacteria of the Enterobacteriaceae family and their representatives Y. enterocolitica and Y. pseudotuberculosis are known as human enteropathogens. The carriers are latently infected warm-blooded animals.

The infection occurs orally after the ingestion of contaminated water or food.

The clinical signs of *Y. enterocolitica* and *Y. pseudotuberculosis* infection are very similar. Differences are mostly observed in intestinal complaints, pseudoappendicitis and sepsis. The most widespread Y. enterocolitica causes diarrhoea in humans, accompanied by diarrhoea of the small intestine, colon or appendix. It can also cause joint inflammation and enlargement of the lymph nodes. Complications such as acute reactive arthritis, erythema nodosum, acute glomerulonephritis and myocarditis may develop during the infection. Arthritis can sometimes develop into a chronic and incurable form. Reactive arthritis is often associated with erythema nodosum, especially in women. Skin symptoms appear about 1–6 weeks after the infection. In some cases, Y. enterocolitica may also persist for years in the intestinal mucosa and in the lymphatic tissues.

Antibody Response

IgA, IgG and IgM antibodies can be detected in the initial phase after contact with virulent Yersinia factors. IgA and IgM titres will decrease after several months.

IgG class antibodies persist longer and can be detected in serum for longer than one year. In chronic forms of the disease and immunopathological complications, the decrease in IgA antibodies may be slower and they may completely disappear only after several years. IgG antibodies may persist in some cases throughout the live.



Prevalence

Yersinosis is the third most common bacterial food disease after salmonellosis and campylobacteriosis, and the fourth the most common zoonosis in many European countries. The highest rates were reported by Finland, Lithuania and Czechia (ECDC 2021).



ELISA

Test Principle

The assays are based on a sandwich type of ELISA method.



Summary Protocol

| Step | | <u>lest steps</u> |
|------|-----|---|
| U | 1. | Dilution of samples - serum/plasma 1:101 (10 µl + 1 ml) |
| ٩ | 2. | Pipette Controls and diluted samples 100 µl - Including blank |
| Ø | 3. | Incubate 30 min. at 37 °C |
| 8 | 4. | Aspirate and wash the wells 5 times |
| ٩ | 5. | Add Conjugate 100 µl - Including blank |
| C | 6. | Incubate 30 min. at 37 °C |
| 8 | 7. | Aspirate and wash the wells 5 times |
| ٩ | 8. | Add 100 µl Substrate (TMB-Complete) - Including blank |
| C | 9. | Incubate 15 min. at 37 °C |
| ٩ | 10. | Add 100 µl Stopping solution - Including blank |
| | 11. | Read colour intensity at 450 nm |

Antigens

Mixture of highly specific recombinant antigens.

Clinical Application

- Screening tests for detection of yersinia infection in humans
- Diagnositics of the disease phase by significant increase or decrease of antibodies

User Comfort

- Ready-to-use components
- Colour-coded components
- Interchangeable components
- Breakable colour-coded microplate strips
- CUT-OFF and calibrators included
- Semiquantitative evaluation of results (Index of Positivity) or quantitative evaluation of results (IU/mI)

Advantages

- High diagnostic specificity and sensitivity
- High reproducibility
- High dynamics of antibody response
- Identical assay procedure
- Short total assay time
- Ready for automation
- Customer support

Test Characteristics

| ELISA | <u>Diagnostic</u> Sensitivity | <u>Diagnostic</u> Specificity |
|------------------|----------------------------------|----------------------------------|
| EIA Yersinia IgA | 90.0% | 99.9% |
| EIA Yersinia IgG | 94.2% | 90.0% |
| EIA Yersinia IgM | 90.0% | 95.0% |

IMMUNOBLOT

Test Principle

Recombinant antigens are transferred to a nitrocellulose membrane using a micro-dispensing method.



Antigens

| BLOT-LINE | | BLO | BLOT-LINE | | BLOT-LINE | |
|------------------|--|------|--|---|--------------------------------------|--|
| Yersi | nia IgA | Yers | Yersinia IgG | | nia IgM | |
| | | | | | | |
| | IgA | | lgG | | Control line | |
| | Start | Н | Start | F | lgM Start | |
| | ҮорВ ҮорD ҮорЕ ҮорН ҮорМ ҮорN | | YopB YopD YopE YopH YopM YopN | | YopB YopD YopE YopH YopN | |
| н | LcrV | | LcrV | H | LcrV | |
| | Ail Invasin | | Ail Invasin | | Ail Invasin | |
| | YstB | | YstB | | YstB | |
| | YscM-Y.Ent YscM-Y.Pst | | YscM-Y.Ent YscM-Y.Pst | | YscM-Y.Ent YscM-Y.Pst | |

Clinical Application

- Detailed determination for the presence of *anti-Yersinia* sp. specific antibodies
- Confirmation of ambiguous results
- Confirmation for ELISA tests



| YopB – Yersinia outer protein, transmembrane protein |
|--|
| YopD – Yersinia outer protein, transmembrane protein |
| YopE – Yersinia outer protein |
| YopH - Yersinia outer protein |
| YopM – Yersinia outer protein |
| YopN - Yersinia outer protein |
| LcrV – Low calcium response Virulence, important for |
| YopD a YopB secretion |
| Ail - Attachment-invasion locus protein early phase, |
| involved in the adhesion and invasion process, and |
| allows yersinia to survive outside the host cell, a signifi- |
| cant virulence factor |
| |

 $\label{eq:starsest} \begin{array}{l} \mbox{Invasin} - \mbox{surface adhesin that binds to $$$$$$$$$$$$$$$$$$$ for the surface of target cells and is important particularly in the first stage of infection, a virulence factor $$$$$$$$$$$

YstB – heat-stable enterotoxin B, responsible for the virulence and pathogenicity of *Y. Enterocolitica* strains, biotype 1A

YscM-Y.ent – Yop proteins translocation protein M (specific for *Y. enterocolitica*)

YscM-Y.pst – Yop proteins translocation protein M (specific for *Y. pseudotuberculosis*)

Summary Protocol

Т

at atoma

C1 ----

| Step | | |
|----------|-----|---|
| ٩ | 1. | Pipette Universal solution 2.5 ml |
| 0 | 2. | Strips soaking 10 min. at room temperature - Shaker |
| 8 | 3. | Aspirate |
| U | 4. | Dilute samples – serum/plasma 1:51 (30 µl + 1.5 ml) |
| ٩ | 5. | Pipette Controls and diluted samples 1.5 ml |
| 0 | 6. | Incubate 30 min. at room temperature - Shaker |
| 8 | 7. | Aspirate samples and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker |
| ١ | 8. | Pipette Conjugate 1.5 ml |
| 0 | 9. | Incubate 30 min. at room temperature - Shaker |
| 8 | 10. | Aspirate Conjugate and wash strips with 1.5 ml of Universal solution 3-times for 5 min. - Shaker |
| ٩ | 11. | Pipette Substrate solution (BCIP/NBT) 1.5 ml |
| U | 12. | Incubate 15 min. at room temperature - Shaker |
| 8 | 13. | Aspirate Substrate solution and wash strips with 2 ml of distilled water 2-times for 5 min. - Shaker |
| M | 14. | Sticking and evaluation of strips |

User Comfort

- Ready-to-use components
- Colour-coded strips
- Positive and Negative controls
- Interchangeable components
- Control line is present on the strip
- Possibility of software evaluation

Advantages

- Identical assay procedure
- Easy interpretation and reproducibility of results
- Sophisticated evaluation software
- High diagnostic efficiency
- Ready for automation
- Customer support

Test Characteristics

| Pathogen | <u>Diagnostic</u> Sensitivity | <u>Diagnostic</u> Specificity |
|---------------------------|----------------------------------|----------------------------------|
| BLOT-LINE Yersinia IgA | 94.2% | 93.9% |
| BLOT-LINE Yersinia IgG | 97.8% | 93.9% |
| BLOT-LINE Yersinia IgM | 90.0% | 95.5% |

IMMUNOBLOT





MICROBLOT-ARRAY

Distribution of Antigens and Control Spots



Description of antigens

- A1 YopB
- A2 YopD
- **A3** YopM
- **A4** YopN
- A5 LcrV
- **A6** Ail
- A7 Invasin
- A8 YscM

Description of control spots

- **R** Reference
- **TC** Test control
- CA Conjugate control IgA
- CG Conjugate control IgG
- OC1 Calibration 1
- **C2** Calibration 2
- **C3** Calibration 3
- **C4** Calibration 4

Protocol Summary

| <u>Step</u> | | <u>Test steps</u> |
|-------------|-----|---|
| ٢ | 1. | Pipette Universal solution 150 µl |
| ŀ | 2. | Strips soaking 10 min. at room temperature |
| 8 | 3. | Aspirate |
| T | 4. | Dilute samples - serum/plasma 1:51 (10 µl + 500 µl) |
| ٩ | 5. | Pipette Controls and diluted samples 100 µl |
| ₽ | 6. | Incubate 30 min. at room temperature |
| ⊜ | 7. | Quick wash using the Universal Solution* |
| 8 | 8. | Aspirate samples and wash strips with 150 μl of Universal solution 3-times for 5 min. |
| ٠ | 9. | Pipette Conjugate 100 µl |
| ₽ | 10. | Incubate 30 min. at room temperature |
| ⊜ | 11. | Quick wash using the Universal Solution* |
| 8 | 12. | Aspirate samples and wash strips with 150 µl of Universal solution 3-times for 5 min. |
| ٩ | 13. | Pipette Substrate solution (BCIP/NBT) 100 µl |
| ₽ | 14. | Incubate 15 min. at room temperature |
| 8 | 15. | Quick wash using the distilled water* |
| 8 | 16. | Aspirate Substrate solution and wash strips with 200 μl of distilled water 2-times for 5 min. |
| | 17. | Dry and evaluate strips |

* In case of using the washer fill the wells up to the rim and aspirate immediately after filling the last well.

User Comfort

- Low sample consumption
- Antigens spotted in triplicate minimizing statistical variation
- Possibility of automatic processing and results evaluation
- Parallel testing of multiple markers simultaneously
- High sensitivity and specificity



Microblot-Array



Test Characteristics

| Pathogen | Diagnostic Sensitivity | Diagnostic Specificity |
|------------------------------|------------------------|-------------------------------|
| Microblot-Array Yersinia IgA | 95.1% | 99.9% |
| Microblot-Array Yersinia IgG | 95.5% | 99.9% |

Interpretation of Results

| <u>lgG</u> | lgA | <u>IgM</u> | Interpretation |
|------------|----------------------|------------|---|
| - | - | - | Negative result. |
| _ | - / + | + | Eventual incipient infection. In order to confirm the results it is necessary to repeat the tests. |
| + | - | - | Persistent IgG antibodies after previous infection. |
| + | border line/low + | - | Previous infection. Beginning of reinfection. |
| + | ++ | - | On-going infection. (IgM not necessarily produced) Repeated infection. Chronic infection. (Chronicity confirmed by tests repeated after the 1st and 3rd months; occurrence of clinical symptoms) |
| + | + | + | On-going infection |



Ordering Information

ELISA

| Cat. No. | Product | No. of Wells | | |
|---|-----------------------|--------------|--|--|
| YeA096 | EIA Yersinia IgA | 96 | | |
| YeG096 | EIA Yersinia IgG | 96 | | |
| YeM096 | EIA Yersinia IgM | 96 | | |
| SK-YeA096 | SmartEIA Yersinia IgA | 96 | | |
| SK-YeG096 | SmartEIA Yersinia IgG | 96 | | |
| SK-YeM096 | SmartEIA Yersinia IgM | 96 | | |
| SmartEIA kits are designed for automated processing using the Agility® analyser | | | | |

IMMUNOBLOT

| Cat. No. | Product | <u>No. of Tests</u> | | |
|--|----------------------------|---------------------|--|--|
| YAL020 | BLOT-LINE Yersinia IgA | 20 | | |
| YGL020 | BLOT-LINE Yersinia IgG | 20 | | |
| YML020 | BLOT-LINE Yersinia IgM | 20 | | |
| BD-YAL020 | BlueBLOT-LINE Yersinia IgA | 24 | | |
| BD-YGL020 | BlueBLOT-LINE Yersinia IgG | 24 | | |
| Swlm03 | Immunoblot Software | 1 | | |
| The BlueBLOT-LINE kits are designed for automatic processing using BlueDiver® analyser | | | | |

MICROBLOT-ARRAY

| Cat. No. | Product | No. of Tests |
|----------|------------------------------|--------------|
| YAMA048 | Microblot-Array Yersinia IgA | 48 |
| YGMA048 | Microblot-Array Yersinia IgG | 48 |
| | leted | |

B TestLine[®]

TestLine Clinical Diagnostics Ltd. Krizikova 68, 612 00 Brno, Czech Republic +420 549 121 203 sales@testlinecd.com www.testlinecd.com

| CERTIFIED | R |
|----------------------|---|
| ISO 9001 · ISO 13485 | |

Company is certified to the quality management system standards ISO 9001 and ISO 13485 for in vitro diagnostics.